skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

42 Total results for product and free and sample content found

Datamonitor Healthcare

Priority Populations For COVID-19 Vaccination: Global Timelines For Deployment

COVID-19 Vaccine

As the COVID-19 pandemic continues, governments worldwide have pinned their hopes on returning to normality on the development of a vaccine. With multiple vaccines currently in late-stage trials, there is promise that a successful vaccine will soon be ready.

Topic Coronavirus Vaccines

Scrip

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

Covid 19 Pfizer vaccine

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Topic Coronavirus Vaccines Sales Earnings

Pink Sheet

Pfizer's COVID-19 Vaccine Will Miss US Election, Bourla Clarifies

Pfizer CEO Albert Bourla

EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least

Topic US Election 2020 Vaccines Coronavirus

Scrip

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

Moderna Coronavirus Cold Chain

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up

Topic Vaccines Coronavirus

Scrip

J&J Says It's Wait And See On COVID-19 Vaccine Delay Outlines Rosier Outlook for 2021

Scrip Covid19 Vaccine J&J

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

Topic Coronavirus Vaccines Clinical Trials

Pink Sheet

VP Debate: Pence Tries Vaccine Hesitancy Jujutsu On Harris

Harris Pence VP Debate

‘Senator, please stop undermining confidence in a vaccine,’ Pence says when confronted with the accusation that the administration is politicizing the COVID vaccine development effort.

Topic Coronavirus Vaccines US Election 2020

Pink Sheet

US FDA 'Flexible' With Vaccine Safety Data Requirements, CBER's Peter Marks Says

Peter Marks CBER Director

The median of two months of follow-up is not absolute, but agency flexibility is limited.

Topic Coronavirus Vaccines

Pink Sheet

Hahn Says COVID Vaccine Review Could Take Months As Trump Floats Rejecting New EUA Guidance

Covid19 HELP Hearing

Commissioner’s comments were yet another sign that US FDA won’t clear a vaccine ahead of the election, but hours later the president suggests the White House may decline to clear the agency’s new guidance on emergency use authorization standards for COVID-19 vaccines, raising new concerns about political interference in any decisions.

Topic Coronavirus Vaccines FDA

Scrip

Dr Reddy's To Steer Russian COVID-19 Vaccine Plans In India

Covid 19 Vaccine Scrip

Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.

Topic Coronavirus Vaccines

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: